Intravenous Irinotecan Plus Oral Ciclosporin
Authors:
- S. JagdevSJS. Jagdev
- D.A. AnthoneyDAD.A. Anthoney
- M.T. SeymourMSM.T. Seymour
- 1 December 2005
- journal article
- Published by Elsevier in Clinical Oncology
- Vol. 17 (8) , 646-649
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/IrinotecanClinical Cancer Research, 2005
- Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II studyAnnals of Oncology, 2004
- Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancerBritish Journal of Cancer, 2004
- Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon CancerJournal of Clinical Oncology, 2003
- Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksAnnals of Oncology, 2001
- Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent PanelJournal of Clinical Oncology, 2001
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998